EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study
| Autor: | Ajala, C, Villa, Zapata L |
|---|---|
| Zdroj: | In Value in Health June 2024 27(6) Supplement:S60-S60 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect